Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

buy
Gritstone Oncology Inc

Start price
Target price
Perf. (%)
€1.86
19.05.22
-
19.05.23
-2.32%
18:01

Risky Investment
buy
Baker Hughes A GE Co.

Start price
Target price
Perf. (%)
€32.55
19.05.22
€37.00
19.05.23
1.43%
18:21

Could be worthwhile Investment >10% per year
Future proof or reliable business model
buy
Forte Biosciences Inc.

Start price
Target price
Perf. (%)
€1.08
18.05.22
-
18.05.23
0.70%
17.05.22

Risky Investment
buy
Forte Biosciences Inc.

Start price
Target price
Perf. (%)
€1.08
18.05.22
-
18.05.23
0.70%
17.05.22

Could be worthwhile Investment >10% per year
Good culture
Capable Management
Dependend from some customers or products
buy
Valmont Industries Inc.

Start price
Target price
Perf. (%)
€238.00
18.05.22
-
18.05.23
-0.84%
19.05.22

buy
Genuine Parts Corp

Start price
Target price
Perf. (%)
€124.86
18.05.22
-
18.05.23
-2.47%
17:53

buy
Cognizant Technology Solutions Corp.

Start price
Target price
Perf. (%)
€69.78
18.05.22
-
18.05.23
-4.79%
18:08

buy
Xylem Inc.

Start price
Target price
Perf. (%)
€79.69
17.05.22
€95.00
17.05.23
-4.30%
18:40

buy
Twitter Inc.

Start price
Target price
Perf. (%)
€34.73
17.05.22
€45.00
17.05.23
0.53%
18:46

Could be worthwhile Investment >10% per year
Known brand
Top 10 in its market
buy
UnitedHealth Group Inc.

Start price
Target price
Perf. (%)
€471.15
17.05.22
-
17.05.23
-4.31%
17:44

buy
Plug Power Inc.

Start price
Target price
Perf. (%)
€14.20
16.05.22
-
16.05.25
6.80%
18:47

Could be worthwhile Investment >10% per year
buy
McDonalds Corp.

Start price
Target price
Perf. (%)
€234.95
16.05.22
-
16.05.25
-7.64%
18:30

Could be worthwhile Investment >10% per year
buy
Teladoc Health Inc

Start price
Target price
Perf. (%)
€30.42
16.05.22
-
16.05.25
-1.27%
18:45

Could be worthwhile Investment >10% per year
Bristol-Myers Squibb

Start price
Target price
Perf. (%)
€72.88
16.05.22
-
16.05.23
-1.28%
17:13

Probably not worthwhile Investment
Business model of the past or high risk
buy
Vertex Energy Inc.

Start price
Target price
Perf. (%)
€13.26
16.05.22
€26.00
16.05.23
5.10%
18:44

Could be very worthwhile Investment >20% year
buy
Stratasys Inc.

Start price
Target price
Perf. (%)
€17.10
16.05.22
-
16.05.23
1.52%
17:47

buy
Apple Inc.

Start price
Target price
Perf. (%)
€140.50
16.05.22
-
16.05.23
-7.69%
18:47

Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
Very high dividend yield expected
EBIT growth > 30% per year expected
buy
Tesla Inc

Start price
Target price
Perf. (%)
€735.00
16.05.22
-
16.05.23
-14.33%
18:47

Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
Undervalued
buy
Axsome Therapeutics Inc

Start price
Target price
Perf. (%)
€28.60
16.05.22
-
16.05.23
3.64%
13:49

Risky Investment
buy
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€59.87
15.05.22
€68.00
15.05.23
-0.35%
18:19

Could be worthwhile Investment >10% per year
positive Cash Flow expected
ROE higher than 15% per year
Normal challenges to pay loans and raise capital
buy
Molecular Templates Inc.

Start price
Target price
Perf. (%)
€1.18
15.05.22
-
15.05.23
-14.11%
10:52

Could be very worthwhile Investment >20% year
Overstock.com

Start price
Target price
Perf. (%)
€28.80
14.05.22
-
14.05.23
-11.37%
18:44

Good culture
EBIT growth >5% per year expected
Higher EBIT margin than peer group
Some uniques
buy
Riot Blockchain Inc.

Start price
Target price
Perf. (%)
€7.76
14.05.22
-
14.05.23
-17.64%
18:39

Risky Investment
buy
Marathon Digital Holdings

Start price
Target price
Perf. (%)
€10.98
14.05.22
-
14.05.23
-17.67%
18:45

Risky Investment
buy
Microsoft Corp.

Start price
Target price
Perf. (%)
€253.95
09.05.22
-
09.05.23
-5.65%
18:46

Revenue growth >5% per year expected
Market Leader or Top 3
Small cyclical dependencies
EBIT growth >5% per year expected